These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30348903)

  • 1. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
    Elsby R; Hare V; Neal H; Outteridge S; Pearson C; Plant K; Gill RU; Butler P; Riley RJ
    Drug Metab Dispos; 2019 Jan; 47(1):1-8. PubMed ID: 30348903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
    Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
    Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Static Model-Based Assessment of OATP1B1-Mediated Drug Interactions with Preincubation-Dependent Inhibitors Based on Inactivation and Recovery Kinetics.
    Taguchi T; Masuo Y; Futatsugi A; Kato Y
    Drug Metab Dispos; 2020 Sep; 48(9):750-758. PubMed ID: 32616544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors.
    Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT
    Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
    Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.
    Seithel A; Eberl S; Singer K; Auge D; Heinkele G; Wolf NB; Dörje F; Fromm MF; König J
    Drug Metab Dispos; 2007 May; 35(5):779-86. PubMed ID: 17296622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
    Lee CK; Choi JS; Choi DH
    Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins.
    Zhang B; Zhan G; Fang Q; Wang F; Li Y; Zhang Y; Zhao L; Zhang G; Li B
    Mol Med Rep; 2019 Nov; 20(5):4713-4722. PubMed ID: 31545497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Screening of Six Protein Kinase Inhibitors for Time-Dependent Inhibition of CYP2C8 and CYP3A4: Possible Implications with regard to Drug-Drug Interactions.
    Filppula AM; Mustonen TM; Backman JT
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):739-748. PubMed ID: 29956478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
    Yamazaki M; Li B; Louie SW; Pudvah NT; Stocco R; Wong W; Abramovitz M; Demartis A; Laufer R; Hochman JH; Prueksaritanont T; Lin JH
    Xenobiotica; 2005 Jul; 35(7):737-53. PubMed ID: 16316932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
    Yang SH; Choi JS; Choi DH
    Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental and Modeling Evidence Supporting the
    Izumi S; Nozaki Y; Lee W; Sugiyama Y
    Drug Metab Dispos; 2022 May; 50(5):541-551. PubMed ID: 35241487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study.
    Kikuchi R; Qian Y; Badawi M; Savaryn JP; Gannu S; Eldred A; Hao S; Salem AH; Liu W; Klein CE; Mohamed MF
    Clin Pharmacol Ther; 2024 Nov; 116(5):1334-1342. PubMed ID: 39102854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
    Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Strong CYP3A4 Inhibition, CYP3A4 Induction, and OATP1B1/3 Inhibition on the Pharmacokinetics of a Single Oral Dose of Sotorasib.
    Cardona P; Dutta S; Houk B
    Clin Pharmacol Drug Dev; 2024 Jul; 13(7):810-818. PubMed ID: 38421129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
    Polli JW; Hussey E; Bush M; Generaux G; Smith G; Collins D; McMullen S; Turner N; Nunez DJ
    Xenobiotica; 2013 Jun; 43(6):498-508. PubMed ID: 23256625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.